Evidence map›Paper›PMID 38418125›Full record

ArticleIn vivo (Athens, Greece)

Unraveling the Impact of

Okan Türk, Nail Demirel, Cumhur Kaan Yaltirik, Mustafa Kaya, Ömer Faruk Şahin, Seda Güleç Yilmaz, Fatma Tuba Akdeniz, Turgay Isbir

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. MicroRNAs as Biomarkers of Brain Tumor.Cancer management and research · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Okan TürkDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey; drokanturk@yahoo.com.
Nail DemirelDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Cumhur Kaan YaltirikDepartment of Neurosurgery, Ümraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Mustafa KayaDepartment of Neurosurgery, Sakarya Training and Research Hospital, Sakarya University, Sakarya, Turkey.
Ömer Faruk ŞahinDepartment of Neurosurgery, Ordu Training and Research Hospital, Ordu, Turkey.
Seda Güleç YilmazDepartment of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
Fatma Tuba AkdenizDepartment of Genetics and Bioengineering, Faculty of Engineering and Nature Sciences, Okan University, Istanbul, Turkey.
Turgay IsbirDepartment of Molecular Medicine, Institute of Health Sciences, Yeditepe University, Istanbul, Turkey.
Sağlık Bilimleri Üniversitesi · TRYeditepe University · TROkan University · TROrdu University · TRSakarya Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMicroRNAs (miRNAs) have been identified as key regulators in various cancer types, including brain tumors. This study aimed to investigate the differential expression of miRNA-17 in glial tumors, cerebral metastases, and normal glial tissues. MATERIALS AND

methodsA total of 42 patients were included in this cross-sectional study. Tissue samples were obtained from patients with glial tumors or cerebral metastases and from normal glial tissues. miRNA-17 expression levels were computed by using real-time polymerase chain reaction. Receiver operating characteristics analysis was used to determine the predictive potential of miRNA-17.

resultsIn this study, we demonstrated a statistically significant difference in miRNA-17 expression levels between glial tumors and the control group (p=0.001), with higher miRNA-17 expression observed in glial tumors. Similarly, there was statistically higher miRNA-17 expression in metastatic cases compared with the control group (p=0.007).

conclusionThese findings suggest miRNA-17 might be a potential biomarker for differentiating glial tumors and cerebral metastases from normal glial tissue, although further research is necessary to validate these findings and investigate the potential role of miRNA-17 in the pathogenesis of these brain tumors.

Indexed as

Brain NeoplasmsGliomaMicroRNAsBiomarkersBiomarkers, TumorCross-Sectional StudiesGene Expression Regulation, NeoplasticHumansPrognosisBiomarkersBiomarkers, TumorMicroRNAsMIRN17 microRNA, humancerebral metastasesglial tumorsmiRNA-17molecular pathogenesis

Identifiers

PMID38418125
PMCPMC10905478
OpenAlexW4392250956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.